Cystic Fibrosis
Progress in phase 2 clinical trial of cystic fibrosis drug candidate reported
Published in Gene Therapy Weekly, July 21st, 2005
Inspire has completed more than 50% of target enrollment in its ongoing phase 2 safety study, which is a double-blind, randomized comparison of 2 doses of denufosol tetrasodium (INS37217 Respiratory) to placebo in 72 patients with CF at 18 clinical centers across the United States.
This second phase 2 trial is being conducted in order to gain a greater understanding of safety and tolerability of denufosol in a broader population of CF patients, including patients with lower lung function and patients using antibiotics and other therapeutics,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-07-21)
More Articles from Gene Therapy Weekly
- Alzheimer Disease
Chimeraplasts offer short-term correction of the apolipoprotein E4 gene - Gene Transfer
Viral 2A peptide stabilizes monoclonal antibody at therapeutic levels - Hematology
Cell type and developmental stage guide the efficacy of RNA interference - Oncology
Interleukin-27 transduction prevents new tumor formation in study animals - Pediatric Oncology
S100A4 antisense oligodeoxynucleotide chokes neuroblastoma cell invasion - Angioplasty
Locally delivered decoy nucleotides fail to staunch restenosis in rabbits - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
